ADAMTS5 and kidney disorder: Pharmacologically, it might be more feasible to target a proteolytic enzyme rather than the entire inflammatory process, so targeting ADAMTS5 as a possible antiremodelling therapy could be relevant in IgAN and other kidney diseases with an inflammatory and scarring component.